重组人白介素-11衍生物治疗恶性肿瘤化疗后血小板减少的临床观察  

Clinical Observation of Recombinant Human Interleukin 11 Derivative in the Treatment of Malignant Tumor Chemotherapy-induced Thrombocytopenia

作　　者：李玉齐[1] 陈斯泽[1] 舒阳春[1] 秦鑫添[1] 刘栋[1] 王希成[1] 

机构地区：[1]广东药学院附属第一医院肿瘤科,广东广州510080

出　　处：《临床医学工程》2015年第10期1351-1353,共3页Clinical Medicine & Engineering

摘　　要：目的通过与重组人白细胞介素-11(吉巨芬)对比,探讨重组人白细胞介素-11衍生物(百杰依)治疗恶性肿瘤化疗后血小板减少的疗效及安全性。方法采用自身对照研究将50例化疗后PLT<50×109/L的恶性肿瘤患者分为百杰依组和吉巨芬组。百杰依组第1疗程接受百杰依(1.5 mg)治疗,第2疗程改用吉巨芬(3 mg)治疗,吉巨芬组用药顺序与百杰依组相反。PLT升至100×109/L以上时停药。观察两组的治疗效果、外周血血小板的变化以及不良反应发生情况。结果两组治疗总有效率比较差异无统计学意义(P>0.05)。百杰依组治疗后血小板严重减少(PLT<20×109/L)持续天数、血小板恢复至正常时间均显著短于吉巨芬组,差异具有统计学意义(P<0.05);两药治疗后患者PLT最低值、PLT<50×109/L持续时间相比无统计学差异(P>0.05)。主要药物不良反应包括乏力、发热、头痛、注射部位疼痛、肌肉及关节疼痛、心悸、颜面四肢浮肿等,停药后可自行消退,两组比较无统计学差异(P>0.05)。结论对比重组人白细胞介素-11,rh IL-11衍生物可缩短化疗后血小板重度下降(PLT<20×109/L)的持续时间及血小板恢复至正常时间,药物不良反应未见明显增加,是一种治疗恶性肿瘤化疗所致血小板减少症的有效、安全的药物。Objective To investigate the efficacy and safety of recombinant human interleukin 11 derivative （Baijieyi） in treatment of malignant tumor chemotherapy-induced thrombocytopenia （CIT） compared with rhIL-11 （Jijufen）. Methods 50 cases of malignant tumor patients whose PLT〈50 × 109/L were divided into Baijieyi group and Jijufen group according to self-control study. Baijieyi group was given Baijieyi （1.5 mg） after the first chemotherapy treatment, and given Jijufen （3 mg） after the second chemotherapy treatment. The medication order of Jijufen group was opposite to Baijieyi group. When patients＇ PLT〉100 × 109/L, the medication was stopped. The treatment effect, changes of peripheral blood platelets and incidence of adverse reactions were compared. Results The total effective rate of two groups had no statistical difference （P〉0.05）. The lasting days of PLT〈20 × 109/L and time of PLT returned to normal level in Baijieyi group were shorter than those in Jijufen group, with statistical difference （P〈0.05）;the minimum value of PLT and lasting days of PLT〈50 × 109/L in two groups had no statistical difference （P〉0.05）. The main adverse reactions included hypodynamia, fever, headache, pain at injection site, muscle and joint pain, palpitation and facial limbs swelling, and all the adverse reactions were resolved spontaneously after stopping medication, the incidence of adverse reactions of two groups had no statistical difference （P〉0.05）. Conclusions Comparing with rhIL-11, rhIL-11 derivative can effectively shorten the lasting days of PLT〈20 × 109/L and time of PLT returned to normal level, without increasing the incidence of adverse reactions, which is an effective and safety pharmaceutical in the treatment of malignant tumor CIT.

关 键 词：重组人白细胞介素-11 恶性肿瘤化疗 血小板减少症 

分 类 号：R730.5[医药卫生—肿瘤]